NSE - Delayed Quote INR
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
1,734.40
-10.90
(-0.62%)
At close: June 13 at 3:30:03 PM GMT+5:30
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
39,179,900
39,179,900
34,841,800
31,165,056
24,242,400
Cost of Revenue
13,165,500
13,165,500
11,820,500
11,847,974
8,429,400
Gross Profit
26,014,400
26,014,400
23,021,300
19,317,082
15,813,000
Operating Expense
17,406,400
17,406,400
15,435,600
13,442,194
11,105,100
Operating Income
8,608,000
8,608,000
7,585,700
5,874,888
4,707,900
Net Non Operating Interest Income Expense
-117,300
-117,300
-443,300
-335,169
-51,200
Pretax Income
8,873,900
8,873,900
7,515,100
5,552,326
5,049,000
Tax Provision
2,278,100
2,278,100
1,988,800
1,452,273
1,188,600
Net Income Common Stockholders
6,595,800
6,595,800
5,526,300
4,098,355
3,853,600
Diluted NI Available to Com Stockholders
6,595,800
6,595,800
5,526,300
4,098,355
3,853,600
Basic EPS
42.45
--
35.66
26.50
24.93
Diluted EPS
41.56
--
34.85
26.17
24.91
Basic Average Shares
155,378.09
--
154,971.96
77,325
154,576.82
Diluted Average Shares
158,705.49
--
158,573.89
78,308.80
154,700.92
Rent Expense Supplemental
--
--
20,169
29,508
13,403
Total Expenses
30,571,900
30,571,900
27,256,100
25,290,168
19,534,500
Net Income from Continuing & Discontinued Operation
6,595,800
6,595,800
5,526,300
4,098,355
3,853,600
Normalized Income
6,595,800
6,595,800
5,526,300
4,042,424.91
3,853,600
Interest Income
--
--
44,277
25,362
9,343
Interest Expense
117,300
117,300
443,300
354,084
51,200
Net Interest Income
-117,300
-117,300
-443,300
-335,169
-51,200
EBIT
8,991,200
8,991,200
7,958,400
5,906,410
5,100,200
EBITDA
10,701,600
10,701,600
9,341,600
7,050,479
5,826,800
Reconciled Cost of Revenue
13,165,500
13,165,500
11,820,500
11,847,974
8,429,400
Reconciled Depreciation
1,710,400
1,710,400
1,383,200
1,144,069
726,600
Net Income from Continuing Operation Net Minority Interest
6,595,800
6,595,800
5,526,300
4,098,355
3,853,600
Total Unusual Items Excluding Goodwill
--
--
328,652
75,741
374,479
Total Unusual Items
--
--
328,652
75,741
374,479
Normalized EBITDA
10,701,600
10,701,600
9,341,600
6,974,738
5,826,800
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
19,810.91
0
3/31/2022 - 7/1/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NEULANDLAB.NS Neuland Laboratories Limited
13,193.00
-1.27%
ALKEM.NS Alkem Laboratories Limited
4,847.50
+0.02%
RPGLIFE.NS RPG Life Sciences Limited
2,341.50
+4.28%
ASTRAZEN.NS AstraZeneca Pharma India Limited
10,509.50
+3.08%
ERIS.NS Eris Lifesciences Limited
1,795.10
+0.22%
INNOVACAP.NS Innova Captab Limited
907.30
-4.04%
AJANTPHARM.NS Ajanta Pharma Limited
2,634.20
-3.52%
KILITCH.NS Kilitch Drugs (India) Limited
454.50
-0.01%
STAR.NS Strides Pharma Science Limited
882.45
+3.32%
MEDICAMEQ.NS Medicamen Biotech Limited
412.75
-1.40%